OS006

OS006 is a preclinical-stage therapeutic candidate being developed by OmniSpirant for the treatment of Acute Respiratory Distress Syndrome (ARDS). It utilizes the company's proprietary OmniSome platform, which consists of bioengineered stem cell-derived extracellular vesicles (exosomes). These exosomes are designed to deliver therapeutic cargo directly to the lungs, likely via inhalation, to modulate lung injury and inflammation. While the specific payload and molecular targets have not been publicly disclosed, the therapy aims to leverage the natural regenerative and anti-inflammatory properties of stem cell exosomes to treat severe respiratory conditions.